Breaking News
Simon Cottle is a founding partner at Stanley Capital which he started in 2018 initially as Stanley Capital Limited which was a consulting firm that then executed two independent sponsor investments with Simon originating both and co-lead on execution.
Stanley Capital Partners LLP is now a European mid-market private equity firm using a research and technology-based approach to identify opportunities in the growing sustainable investment sectors of Healthcare and Resource Efficiency. Stanley Capital targets businesses with the potential of generating EBITDA of $25m to $150m. We partner with management teams, in majority and minority transactions, to transform and grow companies through technological change, operational change and market consolidation.
With over 16 years of direct PE experience, Simon has led 12 platform buy out investments, 50+ bolt-on acquisitions, and four strategic mergers and carve-outs at partner level so far. Simon Cottle served as an IC member and Managing Director at Ardian's Buyout team and was a Director at HgCapital prior to founding SCP in 2018. Simon has a >3x CoC realised track record.
Simon has successfully originated, led or co-led the buyouts of Parts Alliance, GSF, Zenith, Leasedrive, Envision Pharma, Trigo, Essential Pharma, Noden Pharma, Qinecsa Solutions, Laboratoire XO, Arietta.AI and Roboyo.
Simon Cottle holds an MBA from INSEAD, an MA and a Richard Blackwell Scholarship from Oxford University, 2 Oriel College academic prizes and was one of 3 top Scholars at Shrewsbury School. Simon is an Olympian being a GB Olympic semi finalist oarsman in Athens in 2004. Simon made Partner from Associate in 7 years and was in the inaugural 40 under 40 PE News list.
Simon Cottle began his career as an investment banker at Deutsche Bank and Citigroup. He served as Advisory Partner at Gyrus Capital. He also served as Director at HG Capital (UK) and Motion Equity Partners. He served Board Member of Noden Pharma.